Literature DB >> 19691561

Do we still need a malaria vaccine?

B Greenwood1, G Targett.   

Abstract

An unexpectedly large reduction in the burden of malaria has recently been achieved in a number of malaria endemic countries following the scaling up of effective treatment and simple vector control programmes. These achievements question the need for a partially effective malaria vaccine targeted at disease prevention. If an anti-disease vaccine is to replace or supplement existing control measures a high level of efficacy, sustained over a number of years, will be required. Recent successes in malaria control have re-awakened interest in the possibility of malaria elimination in areas where this was not previously considered to be a feasible objective. Malaria vaccines with transmission-blocking properties could play a key role in future elimination programmes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19691561     DOI: 10.1111/j.1365-3024.2009.01140.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  22 in total

1.  Malaria Infection and Gametocyte Carriage Rates in Preparation for Transmission Blocking Vaccine Trials in Bancoumana, Mali.

Authors:  Mahamadoun Hamady Assadou; Issaka Sagara; Sara A Healy; Merepen Agnes Guindo; Mamady Kone; Sintry Sanogo; M'Bouye Doucoure; Sekouba Keita; Ruth D Ellis; Yimin Wu; Freda Omaswa; Patrick E Duffy; Ogobara K Doumbo
Journal:  Am J Trop Med Hyg       Date:  2017-07       Impact factor: 2.345

2.  New ultrastructural analysis of the invasive apparatus of the Plasmodium ookinete.

Authors:  Kailash P Patra; Joseph M Vinetz
Journal:  Am J Trop Med Hyg       Date:  2012-07-16       Impact factor: 2.345

Review 3.  Vaccines against malaria.

Authors:  Amed Ouattara; Matthew B Laurens
Journal:  Clin Infect Dis       Date:  2014-12-01       Impact factor: 9.079

4.  N-terminal prodomain of Pfs230 synthesized using a cell-free system is sufficient to induce complement-dependent malaria transmission-blocking activity.

Authors:  Mayumi Tachibana; Yimin Wu; Hideyuki Iriko; Olga Muratova; Nicholas J MacDonald; Jetsumon Sattabongkot; Satoru Takeo; Hitoshi Otsuki; Motomi Torii; Takafumi Tsuboi
Journal:  Clin Vaccine Immunol       Date:  2011-06-29

5.  Antibodies directed against merozoite surface protein-6 are induced by natural exposure to Plasmodium falciparum in a low transmission environment.

Authors:  S J Jordan; A L Oliveira; A T Neal; J N Hernandez; O H Branch; J C Rayner
Journal:  Parasite Immunol       Date:  2011-07       Impact factor: 2.280

6.  Malaria immunoepidemiology in low transmission: correlation of infecting genotype and immune response to domains of Plasmodium falciparum merozoite surface protein 3.

Authors:  Stephen J Jordan; Ana L Oliveira; Jean N Hernandez; Robert A Oster; Debasish Chattopadhyay; OraLee H Branch; Julian C Rayner
Journal:  Infect Immun       Date:  2011-03-07       Impact factor: 3.441

7.  Allele specificity of gamma interferon responses to the carboxyl-terminal region of Plasmodium falciparum merozoite surface protein 1 by Kenyan adults with naturally acquired immunity to malaria.

Authors:  Michele D Spring; Kiprotich Chelimo; Daniel J Tisch; Peter Odada Sumba; Rosemary Rochford; Carole A Long; James W Kazura; Ann M Moormann
Journal:  Infect Immun       Date:  2010-08-09       Impact factor: 3.441

8.  Limited variation in vaccine candidate Plasmodium falciparum Merozoite Surface Protein-6 over multiple transmission seasons.

Authors:  Aaron T Neal; Stephen J Jordan; Ana L Oliveira; Jean N Hernandez; Oralee H Branch; Julian C Rayner
Journal:  Malar J       Date:  2010-05-24       Impact factor: 2.979

Review 9.  Malaria vaccines: looking back and lessons learnt.

Authors:  Veronique Lorenz; Panagiotis Karanis
Journal:  Asian Pac J Trop Biomed       Date:  2011-01

10.  Combining liver- and blood-stage malaria viral-vectored vaccines: investigating mechanisms of CD8+ T cell interference.

Authors:  Emily K Forbes; Sumi Biswas; Katharine A Collins; Sarah C Gilbert; Adrian V S Hill; Simon J Draper
Journal:  J Immunol       Date:  2011-08-29       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.